Pioneering Telomerase-Activated
Therapies for Neurodegenerative
and Age-Related Diseases

Our Mechanism of Action
Telomerase Activation

Neurodegenerative
Science

The neuroprotective effects of telomerase reverse transcriptase (TERT) in the brain and spinal cord were previously demonstrated by us and by others.

Our compounds demonstrated remarkable therapeutic results in various murine models of neurodegenerative diseases, in a dose- and time-dependent manner.

Our findings support the role of TERT activation in preserving neuronal integrity, reducing inflammation, and improving motor and cognitive function in efficacy models of ALS and Alzheimer’s disease.

In the hSOD1 Tg
murine models of ALS, treatment with AGS-499 delayed the onset and progression of the disease, increased the survival of motor neurons in the mice spinal cord, and increased survival of the mice.

When tested on primary murine hippocampal neurons which were subjected to amyloid beta toxicity, treatment with AGS resulted in increased neuronal survival.

In-vitro testing of AGS
effects on human mesenchymal stem cells derived from ALS and MS patients demonstrated increased survival and ameliorated oxidative stress.

In the 5XFAD murine
model of Alzheimer Disease, AGS treatment reduced amyloid beta plaque burden and improved cognitive behavior.

In human microvessels from coronary artery disease patients, treatment with AGS-499 restored normal vasodilation and demonstrated ability to reverse vascular aging and oxidative damage, re-establishing healthy endothelial function.

AGS treatment in diabetic mice protected pancreatic β-cells, significantly lowered fasting glucose, and improved glucose tolerance. It also preserved kidney structure and normalized creatinine clearance.

AGS compounds stimulated hair regeneration in both newborn and adult mice, increasing the number and activation of hair follicles. Immunofluorescence analyses showed elevated telomerase expression and stem-cell activation within follicles, demonstrating clear rejuvenation of skin and hair tissues.

AGS compounds rejuvenated reproductive function in both sexes with powerful anti-aging effects. In females, they increased ovulation, hormone levels, and embryo count; in males, they boosted sperm production, motility, and restored fertility after damage.

Anti Aging
Science

Our compounds demonstrate strong rejuvenation and anti-aging effects.

By activating telomerase, AGS compounds promote mitochondrial protection, reduce oxidative stress, and preserve cellular vitality.

Our findings support their potential to reverse age-related cellular decline and extend tissue healthspan, as shown across multiple models of cardiovascular, metabolic, reproductive, and hair regrowth.

Pipeline

Team

Prof. Esther Priel, DSc

Founder, CEO & CSO

Daniella Dayan, B.Sc., MBA

Chief Operating Officer

Dr. Helena Grinberg-Rashi,
Ph.D., MBA

Senior Clinical and Regulatory Advisor

Dr. Elad Bar Gil, MD

Chief Medical Officer

Dr. Hananel Elul, Ph.D

Researcher

Dr. Tatyana Glukovsky, Ph.D

Researcher

Scientific Advisory Board

Prof. Gal Ifergane, MD

Head of the Brain Medicine Division,
Soroka Medical Center

Prof. David Stepensky, Ph.D

Prof. of Pharmacology,
Ben-Gurion University

Mr. Iftach Seri, M.Sc. MBA

CEO, CTS Ltd. - pharmaceutical company, Israel

Selected
Scientific
Publications

Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E.

Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis

EMBO Mol Med. 2012 Apr;4(4):313-29. doi: 10.1002/emmm.201200212. Epub 2012 Feb 20.

Tichon A, Eitan E, Kurkalli BG, Braiman A, Gazit A, Slavin S, Beith-Yannai E, Priel E.

Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals

Curr Mol Med. 2013 Jul;13(6):1010-22. doi: 10.2174/1566524011313060013.

Baruch-Eliyahu N, Rud V, Braiman A, Priel E.

Telomerase increasing compound protects hippocampal neurons from amyloid beta toxicity by enhancing the expression of neurotrophins and plasticity related genes

Sci Rep. 2019 Dec 2;9(1):18118. doi: 10.1038/s41598-019-54741-7.

Events & Media

01/07/2025

About Neuromagen with Founder Esther Priel – KAN 11 Feature

10/05/2025

Selected for the Israeli Delegation to the SelectUSA Investment Summit, Washington, D.C., for two consecutive years (2024–2025).

19/04/2024

Breaking Ground in ALS Research – featured by Ynet

27/09/2023

Neuromagen’s Rise in Israel’s Biotech Scene - Featured by TheMarker

19/11/2024

Neuromagen Pharma's team were invited to participate in the round table held by the US Office of Economic Development.

09/07/2025

In Conversation with Prof. Esther Priel: The Vision Behind Neuromagen - featured by Pnima Magazine.

Prof. David Stepensky and Mr. Iftach Seri have joined the scientific advisory board.

Strong Intellectual Property Position

Over 30 patents

All 8 major markets

New IP.
Once granted,
protects
AGP-499
through 2045

Cover for composition & use

Indications:

Neurodegenerative, Fertility, Diabetes,
Cardiovascular diseases, Hair & skin,
AMD

Contact Us

Address

Beer Sheva High Tech Park, 77 HaEnergya St.
P. O. Box 5316, Beer Sheva, Israel

Email

[email protected]

Website

www.neuromagen.com

LinkedIn

Neuromagen Pharma

Privacy Policy | Accessibility Statement

© 2026 Neuromagen Pharma
Design & Development imarkimage

HaEnergia 77, Beer Sheva

Privacy Policy and Cookies

We use cookies on our website, including third-party cookies, to enhance browsing experience, analyze usage, generate statistics, and support personalized advertising and marketing.
Privacy policy and information
Change settings and cookies

Prof. Esther Priel, DSc

Founder, CEO & CSO

Esther is a professor of Molecular Biology and the Head of the Laboratory for Nucleic Acids Topology, at the Faculty of Health Sciences, Ben Gurion University of the Negev. Esther and her research group focus is on the involvement of topoisomerases and telomerase in neurodegenerative diseases, cardiovascular disfunction and diabetes. With more than 40 years of research, Esther and her research group published close to 100 scientific publications, and she is the inventor of more than 80 patents. Esther is considered a world expert in the field of neuroprotection by telomerase.

Esther received her M.Sc. in Human Genetics from Tel Aviv University, and her D.Sc. from the Technion Institute of Technology. She received several academic awards among them the Fulbright scholar award as a visiting scientist in the National Institute of Health in the USA.

Daniella Dayan B.Sc., MBA

Chief Operating Officer

Daniella Dayan holds a B.Sc. in Chemical Engineering and an MBA in Entrepreneurship & Hi-Tech from Ben-Gurion University.
She also completed Ben-Gurion University’s Women Entrepreneurs Program and participated in the Oazis Accelerator Program.

Daniella has experience in fundraising and investor relations, including involvement in investment processes and ongoing engagement with investors.

She brings more than ten years of experience in operational and administrative management, supporting day-to-day and organizational activities.

Her academic background combines analytical training with managerial studies, contributing to her approach to strategic planning, operations, and organizational decision-making.
Overall, Daniella offers a professional background across operational and organizational functions.

Dr. Helena Grinberg-Rashi
Ph.D., MBA

Senior Clinical and Regulatory Advisor

Helena is a life-science executive with over 15 years of experience in leading roles at pharmaceuticals and medical devices companies. Helena has an extensive background in drug development, clinical development, and regulation, with a proven track record of leading the product development process from concept to clinical studies worldwide, and successful regulatory submissions in Europe and in the USA. Helena is the founder and CEO of Titania Technologies, a Netherlands-based strategic consultancy firm. She serves as an advisor and mentor for life-sciences and healthcare entrepreneurs and start-up's. Helena earned her Ph.D. in molecular medicine and human genetics from Tel Aviv University and her MBA from the Richman University (IDC) Hertzlia.

Elad Bar Gil, MD

Chief Medical Officer

Elad is our Chief Medical Officer. He studied medicine at Ben-Gurion University.

Elad brings over a decade of experience in leading and managing teams across diverse roles. During his medical studies, he specialized in pharmacology and neuroscience, gaining in-depth knowledge highly relevant to Neuromagen’s drug mechanism and clinical scope.

Prior to joining Neuromagen, Elad conducted brain tissue research in an Alzheimer’s study, tutored pharmacology and anatomy, led a medical education program for prison inmates, and co-authored a clinical paper in cardiology.

Dr. Hananel Elul,
Ph.D

Researcher

Dr. Hananel Elul completed his Ph.D. studies at the Faculty of Health Sciences, The Ben-Gurion University of the Negev, Beer-Sheva Israel.

His research field focuses on the biology of telomerase in the process of spermatogenesis and the effects of the AGS compounds on male fertility. Dr. Elul acquired extensive experience in Molecular Biology methods and techniques using cell cultures and animal models .

Dr. Tatyana Glukovsky Ph.D

Researcher

Dr. Tatyana Glukhovsky completed her Ph.D. studies at the Faculty of Health Sciences, The Ben-Gurion University of the Negev, Beer-Sheva Israel.

Her research field focuses on the biology of telomerase in the process of cardiovascular diseases and the effects of the AGS compounds on the cardiovascular system. Dr. Glukhovsky acquired extensive experience in Molecular Biology methods and techniques using cell cultures and animal models.

Prof. Gal Ifergane, MD

Head of the Brain Medicine Division, Soroka Medical Center

Prof. Gal Ifergane is a clinical Neurologist, active researcher, health-care executive, and consultant to pharma and biomed startup companies.

He completed his education and training in BGU and Soroka Medical Center in Beer-Sheva, Israel. Since 2012 he has served as the Head of Soroka’s Neurology department. As a Deputy Director of the medical center, Prof. Ifergane created the vision for and led the development of the Brain Medicine Division, which he also currently chairs.

Prof. Ifergane research activity focused on clinical, epidemiological and basic neuroscience in the field of headache, stroke, PTSD and other aspects of clinical neurology. He initiated and participated in several innovation initiatives, focused on the deployment of various digital and biomed technologies in various settings.

Since the beginning of the COVID-19 pandemic he extensively practiced, advocated and developed deployment programs for enhancing availability of medical care during using modern digital channels.

Prof. David Stepensky,
Ph.D

Prof. of Pharmacology,
Ben-Gurion University

Prof. David Stepensky is an Associate Professor at the Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel. He holds PhD degree from the Dept. of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, Israel, and received post-doctoral training at the Dept. of Immunology, Weizmann Institute of Sciences, Rehovot, Israel and at the Dept. of Immunobiology, Yale University, New Haven, CT, USA.

His primary research interests are analysis of pharmacokinetic and pharmacodynamic properties of pharmacological agents (small molecular weight drugs and biopharmaceuticals) and development of nanovesicle- and nanoparticle-based systems that can efficiently deliver these agents to their site of action.

He authors over 50 papers and book chapters, serves as consultant to the Israeli Ministry of Health, pharmaceutical and start-up companies, and delivers customized workshops and courses on drug development, pharmaceutics, pharmacology and other topics of his research expertise.

Mr. Iftach Seri,
M.Sc. MBA

CEO, CTS Ltd. - pharmaceutical company, Israel

Mr. Iftach Seri held various positions in the pharmaceutical field in Israeli and international companies for 28 years. In his last position, he served as the Chief executive officer (CEO) of wavelength Pharmaceuticals, a former subsidiary of Perrigo, and currently serves as CEO of CTS, a private Israeli pharmaceutical company operating in Israel since 1921

In the past, Seri served as Senior Vice President at the Indian company Sun, CEO of New Pharm and CEO of Pharma at Teva Israel. He was also a partner in start-ups in the fields of pharmaceuticals and food and advised companies in the field